Janssen Teams Up With Forma On Tumor Metabolism
This article was originally published in The Pink Sheet Daily
Forma has garnered a deal with J&J subsidiary Janssen Pharmaceuticals to develop and commercialize treatments for tumor metabolism.
You may also be interested in...
With late-stage assets scarce, Campbell Alliance consultants offer tips for spotting early oncology opportunities, as part of Windhover’s Therapeutic Area Partnerships annual showcase of top unpartnered assets. MEI Pharma, Macrogenics and EnGeneIC are among the companies featured this year.
Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.
The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.